What changed
$OGN — BUY 📊
Organon & Co.
🎯 Q1 FY26 | Rev $1B | EPS $0.71 vs $0.85 🔴
💡 Consensus expects accelerating revenue decline and continued margin compression, pricing in a terminal decline scenario. Our variant view is that the miss was largely transitory (e.g., higher legal reserves, inventory adjustments) and that the underlying portfolio's cash generation is stable, implying an excessive discount to peer multiples.
📉 Reward/Risk: 2.7:1
🏢 Business Quality: 4/10 - Portfolio of established, cash-generative but declining products with limited moat; biosimilar growth potential provides modest offset.
📊 Valuation: Cheap — on normalized P/E of ~7x vs pharma peer median of 11x, EV/EBITDA ~5x vs 8-9x peers, and FCF yield >15%, suggesting significant upside if...
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/OGN0617